Form 4: Nurix Therapeutics' Chief Legal Officer, Christine Ring, Executes Stock Option and Sells Shares

Christine Ring, Chief Legal Officer of Nurix Therapeutics, exercised stock options and sold shares on November 4, 2024, according to a Form 4 filing with the SEC.

Summary

• On November 4, 2024, Christine Ring, the Chief Legal Officer of Nurix Therapeutics, Inc. (NRIX), executed a transaction involving the company's stock.
• Ring exercised stock options to acquire 3,290 shares of common stock at a price of $9.57 per share.
• Simultaneously, Ring sold 3,290 shares of common stock at a price of $25 per share.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan.
• Following these transactions, Ring directly owns 28,084 shares of Nurix Therapeutics common stock and 96,389 derivative securities.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard disclosure of insider trading activity. The use of a 10b5-1 plan suggests the transactions were pre-planned.

Industry Context

Form 4 filings are standard disclosures required by the SEC when corporate insiders, like Christine Ring, trade their company's stock. These filings provide transparency into insider transactions and are closely watched by investors for signals about a company's prospects. The use of a 10b5-1 trading plan suggests that these trades were pre-planned and not based on any material non-public information.

Key Dates